306 related articles for article (PubMed ID: 24758342)
1. Soluble receptor for advanced glycation end-products and progression of airway disease.
Iwamoto H; Gao J; Pulkkinen V; Toljamo T; Nieminen P; Mazur W
BMC Pulm Med; 2014 Apr; 14():68. PubMed ID: 24758342
[TBL] [Abstract][Full Text] [Related]
2. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.
Miniati M; Monti S; Basta G; Cocci F; Fornai E; Bottai M
Respir Res; 2011 Mar; 12(1):37. PubMed ID: 21450080
[TBL] [Abstract][Full Text] [Related]
3. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
Pratte KA; Curtis JL; Kechris K; Couper D; Cho MH; Silverman EK; DeMeo DL; Sciurba FC; Zhang Y; Ortega VE; O'Neal WK; Gillenwater LA; Lynch DA; Hoffman EA; Newell JD; Comellas AP; Castaldi PJ; Miller BE; Pouwels SD; Hacken NHTT; Bischoff R; Klont F; Woodruff PG; Paine R; Barr RG; Hoidal J; Doerschuk CM; Charbonnier JP; Sung R; Locantore N; Yonchuk JG; Jacobson S; Tal-Singer R; Merrill D; Bowler RP
Respir Res; 2021 Apr; 22(1):127. PubMed ID: 33906653
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD.
Gopal P; Reynaert NL; Scheijen JL; Schalkwijk CG; Franssen FM; Wouters EF; Rutten EP
Respir Res; 2014 Feb; 15(1):24. PubMed ID: 24564838
[TBL] [Abstract][Full Text] [Related]
5. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.
Cheng DT; Kim DK; Cockayne DA; Belousov A; Bitter H; Cho MH; Duvoix A; Edwards LD; Lomas DA; Miller BE; Reynaert N; Tal-Singer R; Wouters EF; Agustí A; Fabbri LM; Rames A; Visvanathan S; Rennard SI; Jones P; Parmar H; MacNee W; Wolff G; Silverman EK; Mayer RJ; Pillai SG;
Am J Respir Crit Care Med; 2013 Oct; 188(8):948-57. PubMed ID: 23947473
[TBL] [Abstract][Full Text] [Related]
6. The Ser82 RAGE Variant Affects Lung Function and Serum RAGE in Smokers and sRAGE Production In Vitro.
Miller S; Henry AP; Hodge E; Kheirallah AK; Billington CK; Rimington TL; Bhaker SK; Obeidat M; Melén E; Merid SK; Swan C; Gowland C; Nelson CP; Stewart CE; Bolton CE; Kilty I; Malarstig A; Parker SG; Moffatt MF; Wardlaw AJ; Hall IP; Sayers I
PLoS One; 2016; 11(10):e0164041. PubMed ID: 27755550
[TBL] [Abstract][Full Text] [Related]
7. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
[TBL] [Abstract][Full Text] [Related]
8. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.
Cockayne DA; Cheng DT; Waschki B; Sridhar S; Ravindran P; Hilton H; Kourteva G; Bitter H; Pillai SG; Visvanathan S; Müller KC; Holz O; Magnussen H; Watz H; Fine JS
PLoS One; 2012; 7(6):e38629. PubMed ID: 22701684
[TBL] [Abstract][Full Text] [Related]
9. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study.
Coxson HO; Dirksen A; Edwards LD; Yates JC; Agusti A; Bakke P; Calverley PM; Celli B; Crim C; Duvoix A; Fauerbach PN; Lomas DA; Macnee W; Mayer RJ; Miller BE; Müller NL; Rennard SI; Silverman EK; Tal-Singer R; Wouters EF; Vestbo J;
Lancet Respir Med; 2013 Apr; 1(2):129-36. PubMed ID: 24429093
[TBL] [Abstract][Full Text] [Related]
10. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy.
Gopal P; Rutten EP; Dentener MA; Wouters EF; Reynaert NL
Eur J Clin Invest; 2012 Aug; 42(8):807-14. PubMed ID: 22288943
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype.
Miłkowska-Dymanowska J; Białas AJ; Szewczyk K; Kurmanowska Z; Górski P; Piotrowski WJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():3879-3884. PubMed ID: 30568439
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the receptor for advanced glycation end products in liver transplantation.
Navarra T; De Simone P; Del Turco S; Filipponi F; Basta G
Ann Hepatol; 2015; 14(2):190-7. PubMed ID: 25671828
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
[TBL] [Abstract][Full Text] [Related]
14. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease.
Ferhani N; Letuve S; Kozhich A; Thibaudeau O; Grandsaigne M; Maret M; Dombret MC; Sims GP; Kolbeck R; Coyle AJ; Aubier M; Pretolani M
Am J Respir Crit Care Med; 2010 May; 181(9):917-27. PubMed ID: 20133931
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor receptor 2 as a possible marker of COPD in smokers and ex-smokers.
Caram LMO; Ferrari R; Nogueira DL; Oliveira M; Francisqueti FV; Tanni SE; Corrêa CR; Godoy I
Int J Chron Obstruct Pulmon Dis; 2017; 12():2015-2021. PubMed ID: 28744116
[TBL] [Abstract][Full Text] [Related]
16. The association between plasma HMGB1 and sRAGE and clinical outcome in intracerebral hemorrhage.
Lei C; Geng J; Zhong L
J Neuroimmunol; 2020 Aug; 345():577266. PubMed ID: 32470565
[TBL] [Abstract][Full Text] [Related]
17. Soluble RAGE is deficient in neutrophilic asthma and COPD.
Sukkar MB; Wood LG; Tooze M; Simpson JL; McDonald VM; Gibson PG; Wark PA
Eur Respir J; 2012 Mar; 39(3):721-9. PubMed ID: 21920897
[TBL] [Abstract][Full Text] [Related]
18. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
Basta G; Del Turco S; Navarra T; Lee WM;
Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
[TBL] [Abstract][Full Text] [Related]
20. Functional role of soluble receptor for advanced glycation end products in stroke.
Tang SC; Wang YC; Li YI; Lin HC; Manzanero S; Hsieh YH; Phipps S; Hu CJ; Chiou HY; Huang YS; Yang WS; Mattson MP; Arumugam TV; Jeng JS
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):585-94. PubMed ID: 23288172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]